FDA Orange Book · active-ingredient family
Flutemetamol f-18
Flutemetamol f-18 is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:VIZAMYL · NDA 203137
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| VIZAMYLRLD×2 | GE HEALTHCARE | NDA 203137 | — | Oct 25, 2013 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8916131 | Sep 16, 2028 | in 2 yr 3 mo | Product |
Flutemetamol f-18 — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
